MiMedx GroupMDXG +1.15%57 Return-on-Tangible-Equity is -20.05% as of Mar. 2026. GuruFocus rates MDXG with a GF Score™ of 57/100 and a GF Value™ of $6.90 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,199 Biotechnology companies, MiMedx Group ranks better than 89.49% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. MiMedx Group's annualized net income for the quarter that ended in Mar. 2026 was $-43.4 Mil. MiMedx Group's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $216.7 Mil. Therefore, MiMedx Group's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -20.05%.
The historical rank and industry rank for MiMedx Group's Return-on-Tangible-Equity or its related term are showing as below:
MDXG'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -191.5 Med: 25.24 Max: 155.82
Current: 15.36
During the past 13 years, MiMedx Group's highest Return-on-Tangible-Equity was 155.82%. The lowest was -191.50%. And the median was 25.24%.
MDXG's Return-on-Tangible-Equity is ranked better than 89.49% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs MDXG: 15.36
MiMedx Group (NAS:MDXG) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
MiMedx Group Return-on-Tangible-Equity Related Terms
MiMedx Group Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for MiMedx Group's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDXG vs MNPR, FTH, BBOT: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, MiMedx Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiMedx Group Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiMedx Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where MiMedx Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -20.05% mean?
MiMedx Group (MDXG) has a Return-on-Tangible-Equity of -20.05% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MiMedx Group and its competitors. According to the industry distribution chart, MiMedx Group ranks #126 out of 1199 companies in the Biotechnology industry, placing it in the top 10.5%.
Is MiMedx Group's Return-on-Tangible-Equity too high?
MiMedx Group's current Return-on-Tangible-Equity is -20.05%. Based on the distribution chart, MiMedx Group ranks #126 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MiMedx Group has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's Return-on-Tangible-Equity compare to MNPR and FTH?
According to the Biotechnology industry distribution chart, MiMedx Group ranks #126 out of 1199 companies for Return-on-Tangible-Equity. This places MiMedx Group in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MiMedx Group and its competitors. MiMedx Group's current Return-on-Tangible-Equity is -20.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.90, compared to a current price of $3.95 — trading 42.8% below its estimated fair value. The current Return-on-Tangible-Equity is -20.05%. MiMedx Group's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For MiMedx Group (MDXG), the current Return-on-Tangible-Equity is -20.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MiMedx Group (MDXG) Overvalued in 2026?
Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued.
The current stock price of $3.95 is trading 42.8% below its estimated GF Value™ of $6.90.
GuruFocus considers MiMedx Group to be Significantly Undervalued.
Key valuation signals for MDXG:
Return-on-Tangible-Equity: -20.05%
GF Value™: $6.90 vs. price of $3.95 (42.8% below fair value)
No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score
Get the complete analysis for MDXG
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXG has been successfully added to your 
